Jazz Pharmaceuticals presents late-breaking phase 4 data showcasing Xywav
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19-07-2025
- Yahoo
Utah Jazz's Concrete Lauri Markkanen Trade Plans Emerge
The NBA has seen several blockbuster trades executed this offseason, but the Utah Jazz haven't been involved in either sending out or adding star talent. That's despite some strong interest in trading for Lauri Markkanen. While teams may be interested in the one-time All-Star power forward, the Jazz don't appear any closer to trading their Finnish marksman. According to ESPN's NBA expert Tim MacMahon, the Jazz have no plans to trade the 28-year-old this offseason. 'A lot of scouts and executives to wonder whether the Jazz would trade 28-year-old Markkanen next, as new president of basketball operations Austin Ainge takes over as the primary decision-maker in the franchise's is not Utah's intention, sources told ESPN. It would be too much to describe Markkanen as untouchable, but the Jazz still project the All-Star forward as a key player in their future core.' ESPN on Lauri Markkanen trade The Jazz have already traded the likes of Collin Sexton and John Collins, which fueled speculation that Markkanen could be next. Yet that doesn't seem to be in Utah's cards, at least not this offseason. Markkanen is entering the first season of a four-year, $195 million contract with the Jazz, where he'll earn a salary of $46.3 million during the 2025-26 season. Yet, instead of the Jazz trying to trade him for the best package available, Utah would prefer to see how competitive they can be at the start of the season first. Who knows? Perhaps a Markkanen trade is revisited ahead of the trade deadline, but for now, he appears to be off-limits. Related: Related Headlines Los Angeles Clippers Signing 3x All-Star Scorer Philadelphia Eagles Super Bowl Starter Claims Team Traded Him Out of Fear Tigers Slugger Riley Green Turned Down Multiple Home Run Derby Invites? San Diego Padres game today: Includes full 2025 Padres schedule
NBC Sports
15-07-2025
- NBC Sports
Utah Jazz reportedly not looking to trade Lauri Markkanen
John Collins? Traded. Collin Sexton? Traded. Jordan Clarkson? Bought out. Lauri Markkanen? It looks like the veteran forward is staying in Utah and will not be traded, Tim MacMahon reports at ESPN. [Trading Markkanen] is not Utah's intention, sources told ESPN. It would be too much to describe Markkanen as untouchable, but the Jazz still project the All-Star forward as a key player in their future core. While this is what a front office says when trying to gain leverage and drive up the price tag on a potential trade, in this case, there are reasons to believe Utah means it. For one thing, even if Markkanen bounces back to the form of his first season in Utah — when he was an All-Star and won the Most Improved Player award — it's not going to disrupt the clear plan for next season, which is to, how should we put this, end up with excellent lottery odds. Secondly, his massive salary — his four-year, $195.9 million contract extension kicks in this season, starting at $46.4 million — makes finding a workable trade difficult. Finally, and tied to that contract, Markkanen struggled through an injury-plagued last season, averaging 19 points and 5.9 rebounds per game, but his shooting efficiency was down across the board, including 34.6% from 3-point range. Teams are going to want to see the 28-year-old regain his form. Which is to say, the Jazz are going to wait, play Markannen with their young stars like the just-drafted Ace Bailey, Kyle Filipowski (who has looked fantastic at Summer League) and Walker Kessler, and see how things shake out. At the deadline, maybe the Jazz and another team out there will feel differently, maybe not, but for now expect Markkanen to stay in Utah. Where he has wanted to be.
Business Wire
15-07-2025
- Business Wire
IMPLANET Announces CFDA Approval for Its Innovative JAZZ Range in China
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, PEA-PME eligible), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced that its innovative JAZZ range has been approved by the CFDA in China. As part of a distribution partnership signed in November 2022, IMPLANET and Sanyou Medical have successfully registered the JAZZ range, dedicated to tape fixation in the treatment of spinal pathologies, on the Chinese market, the world's largest potential market in terms of volume. This is a major milestone in the strategic partnership with Sanyou Medical. The JAZZ system can be used in combination with the full range of spinal fixation systems already developed by Sanyou Medical, offering Chinese surgeons a complete hybrid surgical solution that is unique in this market. Ludovic Lastennet, CEO of IMPLANET, said: "Obtaining the registration certificates for our JAZZ range from the CFDA, the Chinese health authority, marks a major new turning point for Implanet, and once again attests to the high clinical value of our JAZZ ® technology. Penetration of the Chinese market, through our alliance with SanYou Medical, has been at the heart of our strategy since 2022. SanYou Medical's marketing and commercial strength in China should rapidly provide Implanet with new resources to accelerate its development in one of the world's most important markets. This partnership also demonstrates our ability to develop disruptive technologies that meet the need for innovation in new markets. It is fully in line with our medium-term strategic development plan, based both on the deployment of our direct sales model in France, the United States and high-potential European markets, and on the development of strategic partnerships with major players. We are now working on the commercial launch, which should take place early in the fourth quarter of this year". Strategy and Outlook for 2025 Finalize the registration of existing products under the European Medical Device Regulation (MDR) and the FDA's 510(k). Continue to expand the Company's presence in the United States: Reinforce resources and commercial capabilities for the historical team; Expand the Company's direct approach by enlarging the scientific team of key opinion leaders; Enhance market momentum and expand the product offering: Deploy the commercial and technological partnership with Sanyou Medical for the joint development of a new, innovative European range of hybrid posterior fixation systems; Launch distribution of the JAZZ ® platform in China, the world's largest spine market by volume, in collaboration with Sanyou Medical; Distribute advanced medical technology equipment in Europe, including the ultrasonic surgical scalpel from SMTP Technology Co. Position Implanet as a partner for surgeons and healthcare institutions in terms of Artificial Intelligence and robotics adapted to our implants. Upcoming Financial Communications First Half 2025 results – September 16 th, 2025, after market close About IMPLANET IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributes medical technology equipment. Its activities focus on an innovative solution to improve the treatment of spinal pathologies (JAZZ ®), complemented by the product range of thoraco-lumbar screws, cages, and cervical plates, acquired through Orthopaedic & Spine Development (OSD) in May 2021. In 2022, the Company entered into a commercial, technological, and financial partnership with Sanyou Medical, China's second-largest medical device manufacturer. As part of this strategic agreement, IMPLANET developed in 2024 the Jazz Spinal System™ hybrid fixation system, a unique new range featuring a comprehensive pedicle screw solution, combined with the market's most advanced braided implant technology, JAZZ ®. IMPLANET's orthopedic platform is built on the traceability of its products. Protected by four families of international patents, JAZZ ® has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA), CE marking in Europe, and ANVISA approval in Brazil. IMPLANET employs 46 people and generated €9.4 million in consolidated revenue in 2024. Based near Bordeaux, France, IMPLANET has operated a U.S. subsidiary in Boston since 2013. IMPLANET is listed on the Euronext Growth market in Paris. For more information, visit
